Pythag Tech
Pythag Tech is a New York-based company that uses machine learning trained on proprietary biological data to optimize cultivated-meat growth media, cell lines and bioprocess scale-up, licensing AI-designed production processes to cultivated meat producers.
Position in SVTRnew
Snapshot 2026-10-23- Startup SignalsRankedof 2,331
- Life SciencesRankedof 245
- AI for ScienceRankedof 102
About
Pythag Tech is a New York-based company that uses machine learning trained on proprietary biological data to optimize cultivated-meat growth media, cell lines and bioprocess scale-up, licensing AI-designed production processes to cultivated meat producers. It also runs Clean Meat Terminal, a market-intelligence platform for cellular agriculture.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Investor· 2
Founders / team· 4
Funding history
- 2026-10-22Seed$4M
Investors · Azolla Ventures, Endurance28Source · fortune.com ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Pythag Tech
Pythag Tech is a New York-based company that uses machine learning trained on proprietary biological data to optimize cultivated-meat growth media, cell lines and bioprocess scale-up, licensing AI-designed production processes to cultivated meat producers. It also runs Clean Meat Terminal, a market-intelligence platform for cellular agriculture.
Seed · 2026-10
—
United States
BusinessLatest roundTotal raisedDate- Generate Biomedicines
Generative AI drug development company incubated by Flagship Pioneer, using machine learning to design and create new proteins that can be used to treat diseases
Series C · $693M · 2023-09
$693M - Seismic Therapeutic
Uses machine learning to develop new drugs for autoimmune diseases
Undisclosed · $121M · 2023-12
$121M - Engine Biosciences
Uses machine learning and biology to discover and develop precision oncology drugs
Series A · $27M · 2023-11
$27M
China
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDate- Silvia Bio
Biologics manufacturing process optimization: bioinformatics analysis + cell assay kits + licensable culture media additives
Seed · $4M · 2026-10
$4M - Biographica
Uses machine learning to identify gene-editing targets in crops, accelerating breeding R&D
Seed · $149M · 2026-01
$149M - LabGenius
Machine learning and robotic automation to discover and optimize therapeutic antibodies
Series B · $45M · 2024-05
$45M
Other / unspecified
BusinessLatest roundTotal raisedDate- OutPost Bio
Automated wet lab + machine learning to generate human microbiome data and predict microbial effects of drugs/products
Pre-Seed · $7M · 2026-03
$7M - Cent
Annual preventive health check protocol for consumers: whole-body MRI, low-dose CT, DEXA, ECG/ultrasound and 100+ blood and urine biomarkers, with an in-house AI system synthesizing multimodal imaging and biomarker data into health scores and risk ratings; runs its own clinical prevention centers in Bengaluru, Mumbai and Delhi NCR, and works with Siemens Healthineers to shorten scan times.
$5M
$5M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
39 Life Sciences deals in the last 24 months · 18 at a nearby stage · 35 in NYC Metro
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 31 in NYC Metro
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 11 at a nearby stage · 22 in NYC Metro
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 7 at a nearby stage · 20 in NYC Metro
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 15 in NYC Metro
Request intro →Lightspeed
16 Life Sciences deals in the last 24 months · 5 at a nearby stage · 14 in NYC Metro
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.